Gufic Biosciences Ltd - 509079 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vipula J Choksi GUFIC BIOSCIENCES LTD. - 509079 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vipula J Choksi GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Company will host an Earnings Call (Virtual) for Investors/Analysts on Tuesday, June 08, 2021, at 16:30 hours (IST), during which officials of the Company will discuss the business background/prospects and financial performance of the Company and take questions. Gufic Biosciences Ltd - 509079 - Corporate Action-Board approves Dividend
Recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the financial year ended March 31, 2021, subject to the approval of the Shareholders at the ensuing Annual General Meeting. Gufic Biosciences Ltd - 509079 - Outcome Of The Board Meeting Dated 04.06.2021
The Board of Directors of the Company at its Meeting held on June 04, 2021 inter alia considered and approved the following: 1. Allotment of 1,91,14,506 Equity Shares of the Company of FV of Re. 1/- each to the Shareholders of Gufic Lifesciences Private Limited ('Transferor Company' or 'GLPL') pursuant to the Scheme of Amalgamation of Gufic Lifesciences Private Limited ('Transferor Company') with the Company ('Transferee Company') and their shareholders and creditors. 2. The Audited Financial Results for the quarter and financial year ended March 31, 2021. 3. Recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the financial year ended March 31, 2021, subject to the approval of the Shareholders at the ensuing Annual General Meeting. GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Intimation for Allotment Of Equity Shares Pursuant To The Scheme Of Amalgamation; Approval Of Financial Results For The Quarter And Year Ended March 31, 2021 And Recommendation Of Final Dividend For The Financial Year Ended March 31, 2021, If Any
GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/06/2021 ,inter alia, to consider and approve 1. Allotment of 1,91,14,506 Equity Shares of Re. 1/-each to the shareholders of Gufic Lifesciences Private Limited (Transferor Company) pursuant to the order passed by Hon'ble National Company Law Tribunal (NCLT) Ahmedabad bench dated December 31, 2020 and NCLT Mumbai bench dated March 11, 2021, sanctioning the Scheme of Amalgamation of the Transferor Company with Gufic Biosciences Limited and their respective shareholders and creditors. 2. Approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2021 3. To consider and recommend dividend, if any, for the financial year 2020-21, subject to approval by shareholders at their ensuing Annual General Meeting GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
With regards to the sanction of the Scheme of Amalgamation ('the Scheme') of Gufic Lifesciences Private Limited ('Transferor Company') with Gufic Biosciences Limited ('Company'') and their respective shareholders and creditors by the Hon''ble National Company Law Tribunal, Ahmedabad bench and Mumbai bench vide orders dated December 31, 2020 and March 11,2021 respectively, we wish to inform you that both the Transferor Company and the Company have filed the Certified True Copy of the order with their respective jurisdictional Registrar of Companies and accordingly the captioned Scheme has become operational and pursuant to which, the Transferor Company stands amalgamated with the Company effective from January 01, 2019 Further, pursuant to the provisions of Para II (1) of Annexure 1 of SEBI Circular No. CFD/DIL3/CIR /2017/21 dated March 10, 2017, the documents as required, are enclosed herewith. Kindly take the same on record. Gufic Biosciences Ltd - 509079 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBI Funds Management Pvt Ltd GUFIC BIOSCIENCES LTD. - 509079 - Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
We are pleased to inform you that the Company on May 19, 2021 have received permission from the Central Drugs Standard Control Organization, Ministry of Health And Family Welfare, New Delhi to manufacture and market Liposomal Amphotericin B Injection 50mg/vial (Lyophilized), subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.